← Leaderboards
Gerald I Shulman
Yale University
$43,949,903
Attributed
$50,506,685
Total exposure
52
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$79,272,392 · 57
By mechanism
R01$24,578,358 · 8
P30$14,254,082 · 9
U24$12,791,459 · 5
P01$7,892,074 · 2
RC2$6,551,020 · 1
R24$6,286,695 · 1
Top collaborators
- Kevan C Herold7 shared
- Michael J. Caplan5 shared
- Stefan Somlo5 shared
- Andrew L Goodman4 shared
- Gary W Cline3 shared
- Kitt F Petersen2 shared
Most similar at Yale University
Same institution · by research overlap
- William V Tamborlane$15,237,030
- Gary W Cline$2,391,134
- Roberto J Groszmann$1,658,547
- Douglas Lyle Rothman$20,115,119
- Kitt F Petersen$7,646,269
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusMetabolicResearch PersonnelIn VivoPathogenesisInsulinClinical ResearchObesityDesignLipidsInsulin ResistanceProgramsGlucoseLiverMetabolismInsightHuman SubjectNon-Insulin-Dependent Diabetes MellitusGrantGlucose MetabolismStable IsotopeResourcesMetabolic DiseasesNuclear Magnetic Resonance Spectroscopy
Grant awards (185)
Yale Diabetes Research Center$1,131,880
P30 · FY2025 · DK · contact PI
Yale Center for Metabolic Phenotyping in Live Models of Obesity and Diabetes$762,924
U2C · FY2025 · DK · contact PI
Targeting hepatic mitochondrial oxidation to treat NAFLD, NASH and type 2 diabetes$647,207
R01 · FY2025 · DK · contact PI
Mechanism of Renal Cortical Insulin Resistance$572,800
R01 · FY2025 · DK · contact PI
Clinical Metabolism Core$298,505
P30 · FY2025 · DK · contact PI
Administrative Core$254,309
U2C · FY2025 · DK · contact PI
Phenotyping Core$254,307
U2C · FY2025 · DK · contact PI
Administrative Core$181,844
P30 · FY2025 · DK · contact PI
Yale Diabetes Research Center$1,151,723
P30 · FY2024 · DK · contact PI
Yale Center for Metabolic Phenotyping in Live Models of Obesity and Diabetes$748,333
U2C · FY2024 · DK · contact PI
Targeting hepatic mitochondrial oxidation to treat NAFLD, NASH and type 2 diabetes$728,612
R01 · FY2024 · DK · contact PI
Phenotyping Core$565,107
U2C · FY2024 · DK · contact PI
Mechanism of Renal Cortical Insulin Resistance$549,889
R01 · FY2024 · DK · contact PI
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates$507,645
R01 · FY2024 · DK · contact PI
Clinical Metabolism Core$299,462
P30 · FY2024 · DK · contact PI
Administrative Core$181,845
P30 · FY2024 · DK · contact PI
Administrative Core$147,472
U2C · FY2024 · DK · contact PI
In vivo Pathway Discovery in Autosomal Dominant Polycystic Kidney Disease$1,265,317
RC2 · FY2023 · DK
Yale Diabetes Research Center$1,165,890
P30 · FY2023 · DK · contact PI
Yale Center for Metabolic Phenotyping in Live Models of Obesity and Diabetes$795,618
U2C · FY2023 · DK · contact PI
Phenotyping Core$604,759
U2C · FY2023 · DK · contact PI
Mechanism of Renal Cortical Insulin Resistance$572,800
R01 · FY2023 · DK · contact PI
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates$532,148
R01 · FY2023 · DK · contact PI
Clinical Metabolism Core$299,460
P30 · FY2023 · DK · contact PI
Administrative Core$181,843
P30 · FY2023 · DK · contact PI
Administrative Core$153,614
U2C · FY2023 · DK · contact PI
Yale Diabetes Research Center$1,674,998
P30 · FY2022 · DK · contact PI
In vivo Pathway Discovery in Autosomal Dominant Polycystic Kidney Disease$1,289,362
RC2 · FY2022 · DK
Mechanism of Renal Cortical Insulin Resistance$572,800
R01 · FY2022 · DK · contact PI
Clinical Metabolism Core$243,403
P30 · FY2022 · DK · contact PI
Yale Diabetes Research Center$1,674,998
P30 · FY2021 · DK · contact PI
In vivo Pathway Discovery in Autosomal Dominant Polycystic Kidney Disease$1,312,677
RC2 · FY2021 · DK
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin Resistance$729,407
R01 · FY2021 · DK · contact PI
Microbiome origins and insulin regulatory responses of the short chain fatty acid acetate$607,517
R01 · FY2021 · DK
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates$534,995
R01 · FY2021 · DK · contact PI
Glucagon Regulation of Hepatic Mitochondrial Activity and Glucose Metabolism by InsP3R-1$418,750
R01 · FY2021 · DK · contact PI
Clinical Metabolism Core$243,401
P30 · FY2021 · DK · contact PI
Yale Diabetes Research Center$1,674,998
P30 · FY2020 · DK · contact PI
In vivo Pathway Discovery in Autosomal Dominant Polycystic Kidney Disease$1,332,350
RC2 · FY2020 · DK
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin Resistance$729,407
R01 · FY2020 · DK · contact PI
Microbiome origins and insulin regulatory responses of the short chain fatty acid acetate$607,517
R01 · FY2020 · DK
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates$538,512
R01 · FY2020 · DK · contact PI
Glucagon Regulation of Hepatic Mitochondrial Activity and Glucose Metabolism by InsP3R-1$418,750
R01 · FY2020 · DK · contact PI
Clinical Metabolism Core$243,403
P30 · FY2020 · DK · contact PI
Yale Diabetes Research Center$1,674,998
P30 · FY2019 · DK · contact PI
In vivo Pathway Discovery in Autosomal Dominant Polycystic Kidney Disease$1,351,314
RC2 · FY2019 · DK
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin Resistance$729,407
R01 · FY2019 · DK · contact PI
Microbiome origins and insulin regulatory responses of the short chain fatty acid acetate$607,517
R01 · FY2019 · DK
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates$557,732
R01 · FY2019 · DK · contact PI
Glucagon Regulation of Hepatic Mitochondrial Activity and Glucose Metabolism by InsP3R-1$418,750
R01 · FY2019 · DK · contact PI
Clinical Metabolism Core$243,401
P30 · FY2019 · DK · contact PI
Administrative Core$167,954
P30 · FY2019 · DK · contact PI
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin Resistance$733,997
R01 · FY2018 · DK · contact PI
Microbiome origins and insulin regulatory responses of the short chain fatty acid acetate$581,617
R01 · FY2018 · DK
Glucagon Regulation of Hepatic Mitochondrial Activity and Glucose Metabolism by InsP3R-1$418,750
R01 · FY2018 · DK · contact PI
Clinical Metabolism Core$219,598
P30 · FY2018 · DK · contact PI
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin Resistance$733,997
R01 · FY2017 · DK · contact PI
CLINICAL METABOLISM CORE$159,828
P30 · FY2017 · DK · contact PI
Yale Mouse Metabolic Phenotyping Center$492,984
U2C · FY2016 · DK · contact PI
Integrative Physiology Core$276,375
U2C · FY2016 · DK · contact PI
CLINICAL METABOLISM CORE$159,828
P30 · FY2016 · DK · contact PI
Administrative Core$99,082
U2C · FY2016 · DK · contact PI
Yale Mouse Metabolic Phenotyping Center$840,442
U24 · FY2015 · DK · contact PI
Integrative Physiology Core$390,657
U24 · FY2015 · DK · contact PI
Mechanisms of Lipid-Induced Hepatic Insulin Resistance$341,325
R01 · FY2015 · DK · contact PI
Animal Care Core$216,653
U24 · FY2015 · DK · contact PI
Metabolomics Core$211,189
U24 · FY2015 · DK · contact PI
CLINICAL METABOLISM CORE$159,828
P30 · FY2015 · DK · contact PI
ADMINISTRATIVE Core$21,943
U24 · FY2015 · DK · contact PI
Genetic and Cellular Mechanisms of NAFLD and Hepatic Insulin Resistance$1,255,263
R24 · FY2014 · DK · contact PI
Yale Mouse Metabolic Phenotyping Center$840,442
U24 · FY2014 · DK · contact PI
Cellular Mechanisms of Insulin Resistance in Humans$536,172
R01 · FY2014 · DK · contact PI
Integrative Physiology Core$381,090
U24 · FY2014 · DK · contact PI
Mechanisms of Lipid-Induced Hepatic Insulin Resistance$341,325
R01 · FY2014 · DK · contact PI
Animal Care Core$231,840
U24 · FY2014 · DK · contact PI
Metabolomics Core$206,054
U24 · FY2014 · DK · contact PI
CLINICAL METABOLISM CORE$159,828
P30 · FY2014 · DK · contact PI
ADMINISTRATIVE Core$21,458
U24 · FY2014 · DK · contact PI
Genetic and Cellular Mechanisms of NAFLD and Hepatic Insulin Resistance$1,219,675
R24 · FY2013 · DK · contact PI
Yale Mouse Metabolic Phenotyping Center$811,026
U24 · FY2013 · DK · contact PI
Cellular Mechanisms of Insulin Resistance in Humans$526,293
R01 · FY2013 · DK · contact PI
Integrative Physiology Core$487,631
U24 · FY2013 · DK · contact PI
Mechanisms of Lipid-Induced Hepatic Insulin Resistance$328,967
R01 · FY2013 · DK · contact PI
Animal Care Core$252,191
U24 · FY2013 · DK · contact PI
Metabolomics Core$194,108
U24 · FY2013 · DK · contact PI
CLINICAL METABOLISM CORE$191,775
P30 · FY2013 · DK · contact PI
ADMINISTRATIVE Core$20,233
U24 · FY2013 · DK · contact PI
Genetic and Cellular Mechanisms of NAFLD and Hepatic Insulin Resistance$1,271,028
R24 · FY2012 · DK · contact PI
Yale Mouse Metabolic Phenotyping Center$840,442
U24 · FY2012 · DK · contact PI
Cellular Mechanisms of Insulin Resistance in Humans$547,772
R01 · FY2012 · DK · contact PI
Integrative Physiology Core$363,778
U24 · FY2012 · DK · contact PI
Mechanisms of Lipid-Induced Hepatic Insulin Resistance$339,873
R01 · FY2012 · DK · contact PI
Animal Care Core$259,742
U24 · FY2012 · DK · contact PI
Metabolomics Core$196,424
U24 · FY2012 · DK · contact PI
ADMINISTRATIVE Core$20,498
U24 · FY2012 · DK · contact PI
Genetic and Cellular Mechanisms of NAFLD and Hepatic Insulin Resistance$1,280,987
R24 · FY2011 · DK · contact PI
Yale Mouse Metabolic Phenotyping Center$840,442
U24 · FY2011 · DK · contact PI
Cellular Mechanisms of Insulin Resistance in Humans$550,192
R01 · FY2011 · DK · contact PI
Integrative Physiology Core$437,503
U24 · FY2011 · DK · contact PI
Mechanisms of Fat Induced Insulin Resistance$325,873
R01 · FY2011 · DK · contact PI
ADMINISTRATIVE Core$23,681
U24 · FY2011 · DK · contact PI
Genetic and Cellular Mechanisms of NAFLD and Hepatic Insulin Resistance$1,259,742
R24 · FY2010 · DK · contact PI
Cellular Mechanisms of Insulin Resistance in Humans$764,317
R01 · FY2010 · DK · contact PI
Mechanisms of Fat Induced Insulin Resistance$329,165
R01 · FY2010 · DK · contact PI
Mechanisms of Fat Induced Insulin Resistance$332,490
R01 · FY2009 · DK · contact PI
Mitochrondrial Dysfunction: Role in Metabolic Syndrome$1,410,977
P01 · FY2008 · DK · contact PI
Mechanisms of Fat Induced Insulin Resistance$332,071
R01 · FY2008 · DK · contact PI
Role of Mitochondrial Dysfunction in Insulin Resistance$248,397
P01 · FY2008 · DK · contact PI
Mitochrondrial Dysfunction: Role in Metabolic Syndrome$1,397,845
P01 · FY2007 · DK · contact PI
Mechanisms of Fat Induced Insulin Resistance$338,250
R01 · FY2007 · DK · contact PI
Role of Mitochondrial Dysfunction in Insulin Resistance$246,213
P01 · FY2007 · DK · contact PI
Mitochrondrial Dysfunction: Role in Metabolic Syndrome$1,397,966
P01 · FY2006 · DK · contact PI
Mechanisms of Fatty Acid Induced Insulin Resistance$316,122
R01 · FY2006 · DK · contact PI
Role of Mitochondrial Dysfunction in Insulin Resistance$148,437
P01 · FY2006 · DK · contact PI
Mitochrondrial Dysfunction: Role in Metabolic Syndrome$1,390,223
P01 · FY2005 · DK
Yale Mouse Metabolic Phenotyping Center$492,262
U24 · FY2005 · DK
Mechanisms of Fatty Acid Induced Insulin Resistance$323,730
R01 · FY2005 · DK
Role of Mitochondrial Dysfunction in Insulin Resistance$144,228
P01 · FY2005 · DK
DIFFERENCES BETWEEN INSULIN RESISTANT AND NON-INSULIN RESISTANT INDIVIDUALS$51,165
M01 · FY2005 · RR
LIVER LIPID AND CARBOHYDRATE METABOLISM IN FAMIAL HYPERTRIGLYCERIDEMIA$12,792
M01 · FY2005 · RR
REGULATION OF UCP-3 ACTIVITY AND EXPRESSION IN MUSCLE$7,939
M01 · FY2005 · RR
Mitochrondrial Dysfunction: Role in Metabolic Syndrome$1,364,566
P01 · FY2004 · DK
Yale Mouse Metabolic Phenotyping Center$892,262
U24 · FY2004 · DK
CELLULAR MECHANISMS OF INSULIN RESISTANCE IN HUMANS$510,161
R01 · FY2004 · DK
Mechanisms of Fatty Acid Induced Insulin Resistance$323,730
R01 · FY2004 · DK
Metabolic and endocrine defects in lean, non-diabetic offspring of NIDDM paren$216,096
M01 · FY2004 · RR
NMR Measurements of Liver and Muscle Triglyceride Content in N/IR States$208,079
M01 · FY2004 · RR
Metabolic and Physiologic Differences Between Insulin Resistant and Non-Insulin$149,968
M01 · FY2004 · RR
Role of Mitochondrial Dysfunction in Insulin Resistance$143,222
P01 · FY2004 · DK
Regulation of UCP-3 Activity and Expression in Muscle$58,371
M01 · FY2004 · RR
Regulation of Brain Metabolite Synthesis by Ketones in$55,008
M01 · FY2004 · RR
Regulation of Pathways of Glycogen Repletion in Non, Pre, and Diabetic Humans$36,198
M01 · FY2004 · RR
Yale Mouse Metabolic Phenotyping Center$32,700
U24 · FY2004 · DK
Fatty Liver /Hepatic Insulin Resistance from High Fat Fe$21,072
M01 · FY2004 · RR
Effects of FXR Activation on Hepatic Lipid and Carbohydrate Metabolism$10,344
M01 · FY2004 · RR
Yale Mouse Metabolic Phenotyping Center$892,262
U24 · FY2003 · DK
CELLULAR MECHANISMS OF INSULIN RESISTANCE IN HUMANS$501,309
R01 · FY2003 · DK
Mechanisms of Fatty Acid Induced Insulin Resistance$323,730
R01 · FY2003 · DK
Yale Mouse Metabolic Phenotyping Center$40,000
U24 · FY2003 · DK
Yale Mouse Metabolic Phenotyping Center$1,042,682
U24 · FY2002 · DK
CELLULAR MECHANISMS OF INSULIN RESISTANCE IN HUMANS$492,077
R01 · FY2002 · DK
IN VIVO NMR STUDIES OF CARBOHYDRATE METABOLISM$291,066
R01 · FY2002 · DK
CORE--CLINICAL METABOLISM$0
P30 · FY2002 · DK
CORE--CLINICAL METABOLISM$0
P30 · FY2002 · DK
CORE--CLINICAL METABOLISM$0
P30 · FY2002 · DK
Yale Mouse Metabolic Phenotyping Center$1,289,824
U24 · FY2001 · DK
CELLULAR MECHANISMS OF INSULIN RESISTANCE IN HUMANS$482,221
R01 · FY2001 · DK
IN VIVO NMR STUDIES OF CARBOHYDRATE METABOLISM$282,587
R01 · FY2001 · DK
CORE--CLINICAL METABOLISM$254,111
P30 · FY2001 · DK
MECHANISMS OF INSULIN RESISTANCE IN OLDER PERSONS$216,966
P60 · FY2001 · AG
MECHANISMS OF INSULIN RESISTANCE IN OLDER PERSONS$0
P60 · FY2001 · AG
CORE--CLINICAL METABOLISM$0
P30 · FY2001 · DK
CORE--CLINICAL METABOLISM$0
P30 · FY2001 · DK
CORE--CLINICAL METABOLISM$0
P30 · FY2001 · DK
Epinephrine on hepatic glycogenolysis &gluconeogenesis$0
M01 · FY2001 · RR
NMR of triglyceride content inmuscle in insulin resistan$0
M01 · FY2001 · RR
Aspirin in insulin stimulated carbohydrate metabolism$0
M01 · FY2001 · RR
Metabolism/physiology in insulin&noninsulin resistant$0
M01 · FY2001 · RR
CORTICAL GLUTAMATE, GLUTAMINE &GABA LEVELS IN HEPATIC ENCEPHALOPATHY$0
M01 · FY2001 · RR
HEPATIC GLUCOSE METABOLISM IN IDDM (TYPE I) AND NIDDM (TYPE II)$0
M01 · FY2001 · RR
QUANTITAION OF NET HEPATIC GLYCOGENOLYSIS AND GLUCONEOGENESIS WITH METFORMIN$0
M01 · FY2001 · RR
METABOLIC AND ENDOCRINE DEFICITS IN LEAN NONDIABETIC OFFSPRING OF IDDM PATIENTS$0
M01 · FY2001 · RR
MECHANISM OF TROGLITAZONE ACTION IN TYPE II DIABETES MELLITUS$0
M01 · FY2001 · RR
EFFECTS OF FATTY ACIDS ON MUSCLE GLYCOGEN SYNTHESIS$0
M01 · FY2001 · RR
REGULATION OF PATHWAYS OF GLYCOGEN REPLETION IN PREDIABETICS AND DIABETICS$0
M01 · FY2001 · RR
QUANTITATION OF HEPATIC GLYCOGENOLYSIS AND GLUCONEOGENESIS DURING FASTING$0
M01 · FY2001 · RR
CELLULAR MECHANISMS OF INSULIN RESISTANCE IN HUMANS$472,661
R01 · FY2000 · DK
IN VIVO NMR STUDIES OF CARBOHYDRATE METABOLISM$274,356
R01 · FY2000 · DK
MECHANISMS OF INSULIN RESISTANCE IN OLDER PERSONS$216,966
P60 · FY2000 · AG
CORE--CLINICAL METABOLISM$215,280
P30 · FY2000 · DK
MECHANISMS OF INSULIN RESISTANCE IN OLDER PERSONS$157,506
P60 · FY2000 · AG
MRS ASSESSMENT OF MUSCLE GLYCOGEN UTILIZATION DURING PROLONGED EXERCISE$34,535
M01 · FY2000 · RR
QUANTITATION OF HEPATIC GLYCOGENOLYSIS AND GLUCONEOGENESIS DURING FASTING$34,535
M01 · FY2000 · RR
MECHANISM OF TROGLITAZONE ACTION IN TYPE II DIABETES MELLITUS$34,535
M01 · FY2000 · RR
EFFECTS OF FATTY ACIDS ON MUSCLE GLYCOGEN SYNTHESIS$34,535
M01 · FY2000 · RR
REGULATION OF PATHWAYS OF GLYCOGEN REPLETION IN PREDIABETICS AND DIABETICS$34,535
M01 · FY2000 · RR
ASSESSMENT OF INTRACELLULAR FREE GLUCOSE CONSENTRATION IN INSULIN RESISTANCE$34,535
M01 · FY2000 · RR
CORTICAL GLUTAMATE, GLUTAMINE &GABA LEVELS IN HEPATIC ENCEPHALOPATHY$34,535
M01 · FY2000 · RR
HEPATIC GLUCOSE METABOLISM IN IDDM (TYPE I) AND NIDDM (TYPE II)$34,535
M01 · FY2000 · RR
QUANTITAION OF NET HEPATIC GLYCOGENOLYSIS AND GLUCONEOGENESIS WITH METFORMIN$34,535
M01 · FY2000 · RR
METABOLIC AND ENDOCRINE DEFICITS IN LEAN NONDIABETIC OFFSPRING OF IDDM PATIENTS$34,535
M01 · FY2000 · RR
Epinephrine on hepatic glycogenolysis &gluconeogenesis$0
M01 · FY2000 · RR
NMR of triglyceride content inmuscle in insulin resistan$0
M01 · FY2000 · RR
Aspirin in insulin stimulated carbohydrate metabolism$0
M01 · FY2000 · RR
Metabolism/physiology in insulin&noninsulin resistant$0
M01 · FY2000 · RR